How I Treat How I treat splanchnic vein thrombosis

M.A. is a 73-year-old white man who presented to our Thrombosis Center 2 days after ultrasonographic diagnosis of occlusive portal vein thrombosis (PVT). He had known liver cirrhosis secondary to chronic alcohol consumption (Child class A). The ultrasound test was ordered because the patient complained of abdominal pain during the previous 5 days. The remaining clinical history was unremarkable with the exception of arterial hypertension and recurrent episodes of hemorrhoidal bleeding. The patient was prescribed a calcium-channel blocking drug. Laboratory tests revealed an international normalized ratio of 1.3, a prothrombin time ratio of 1.4, an activated partial thromboplastin time of 35 seconds (laboratory reference range, between 25 and 40 seconds) with a ratio of 1.1, and a platelet count of 90 000/mm. Estimated glomerular filtration rate was 60 mL/minute. Upper gastrointestinal endoscopywas immediately ordered to check the presence of esophageal varices, and the patient was temporarily started on intermediate-dose low-molecular-weight heparin (LMWH) (1mg/kg once a day), pending endoscopy. Grade 1 esophageal varices and amild congestive gastropathy were detected, and treatment with LMWH was continued at the usual full therapeutic dose of 1 mg/kg twice a day. Propranolol for the primary prevention of variceal bleeding was also started. As no bleeding events occurred and as the hemoglobin level remained stable at the follow-up visit on day 10, it was decided to continue treatmentwithLMWHfor a total of 1month and then to switch the patient to warfarin, with a target therapeutic range international normalized ratio between 2 and 3, for an indefinite period of time. Complete recanalization of the thrombosis was observed at an ultrasound test performed at 3 months.

[1]  R. Wadhera,et al.  Mesenteric Venous Thrombosis , 2015, Circulation.

[2]  R. Vuppalanchi,et al.  Treatment of acute portal vein thrombosis by nontraditional anticoagulation , 2014, Hepatology.

[3]  W. Ageno,et al.  Antithrombotic Treatment of Splanchnic Vein Thrombosis: Results of an International Registry , 2012, Seminars in Thrombosis & Hemostasis.

[4]  J. Babatz,et al.  Successful treatment of acute portal vein thrombosis with rivaroxaban , 2013, Thrombosis and Haemostasis.

[5]  P. Hillmen,et al.  Thrombosis in paroxysmal nocturnal hemoglobinuria. , 2013, Blood.

[6]  H. Janssen,et al.  Anticoagulant therapy in patients with non‐cirrhotic portal vein thrombosis: effect on new thrombotic events and gastrointestinal bleeding , 2013, Journal of thrombosis and haemostasis : JTH.

[7]  D. Valla,et al.  Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. , 2012, Blood.

[8]  W. Ageno,et al.  Antithrombotic Treatment of Splanchnic Vein Thrombosis: Results of an International Registry , 2012 .

[9]  E. Tsochatzis,et al.  Prospective evaluation of anticoagulation and transjugular intrahepatic portosistemic shunt for the management of portal vein thrombosis in cirrhosis , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[10]  Paolo Prandoni,et al.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[11]  W. Ageno,et al.  Incidental diagnosis of a deep vein thrombosis in consecutive patients undergoing a computed tomography scan of the abdomen: a retrospective cohort study , 2012, Journal of thrombosis and haemostasis : JTH.

[12]  K. Ghosh,et al.  Thrombophilic dimension of Budd chiari syndrome and portal venous thrombosis--a concise review. , 2011, Thrombosis research.

[13]  A. Bergquist,et al.  The epidemiology and clinical features of portal vein thrombosis: a multicentre study , 2010, Alimentary pharmacology & therapeutics.

[14]  I. Martinelli,et al.  Splanchnic vein thrombosis: clinical presentation, risk factors and treatment , 2010, Internal and emergency medicine.

[15]  D. Hodge,et al.  Survival and recurrence in patients with splanchnic vein thromboses. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[16]  D. Valla,et al.  Acute portal vein thrombosis unrelated to cirrhosis: A prospective multicenter follow‐up study , 2010, Hepatology.

[17]  F. Rosendaal,et al.  Etiology, management, and outcome of the Budd-Chiari syndrome. , 2009, Annals of internal medicine.

[18]  W. Ageno,et al.  Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists , 2009, Thrombosis and Haemostasis.

[19]  W. Ageno,et al.  JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. , 2009, Blood.

[20]  D. Valla,et al.  Vascular disorders of the liver , 2009, Hepatology.

[21]  E. Björnsson,et al.  Budd‐Chiari syndrome in Sweden: epidemiology, clinical characteristics and survival – an 18‐year experience , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[22]  S. Acosta,et al.  Epidemiology, risk and prognostic factors in mesenteric venous thrombosis , 2008, The British journal of surgery.

[23]  J. Bismuth,et al.  Prognostic Factors and Treatment Outcome in Mesenteric Vein Thrombosis , 2008, Vascular and endovascular surgery.

[24]  M. Gianni,et al.  Inherited thrombophilic abnormalities and risk of portal vein thrombosis , 2008, Thrombosis and Haemostasis.

[25]  M. Margaglione,et al.  Prognostic Factors in Noncirrhotic Patients With Splanchnic Vein Thromboses , 2007, The American Journal of Gastroenterology.

[26]  P. Kamath Budd‐Chiari syndrome: Radiologic findings , 2006, Liver transplantation.

[27]  D. Valla,et al.  Nonmalignant portal vein thrombosis in adults , 2006, Nature Clinical Practice Gastroenterology &Hepatology.

[28]  À. Rovira,et al.  Noncirrhotic portal vein thrombosis exhibits neuropsychological and MR changes consistent with minimal hepatic encephalopathy , 2006, Hepatology.

[29]  A. Burroughs,et al.  Liver transplantation for Budd-Chiari syndrome: A European study on 248 patients from 51 centres. , 2006, Journal of hepatology.

[30]  Neal Young,et al.  Diagnosis and management of paroxysmal nocturnal hemoglobinuria. , 2005, Blood.

[31]  E. Cholongitas,et al.  Update on the classification, assessment of prognosis and therapy of Budd–Chiari syndrome , 2005, Nature Clinical Practice Gastroenterology &Hepatology.

[32]  F. Rosendaal,et al.  Determinants of survival and the effect of portosystemic shunting in patients with Budd‐Chiari syndrome , 2004, Hepatology.

[33]  D. Valla,et al.  Budd-Chiari syndrome: a review by an expert panel. , 2003, Journal of hepatology.

[34]  W. Tzeng,et al.  CT of small bowel ischemia , 2003, Abdominal Imaging.

[35]  T. Weber,et al.  Noninvasive assessment of portomesenteric venous thrombosis: current concepts and imaging strategies. , 2002, Journal of computer assisted tomography.

[36]  D. Valla,et al.  Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. , 2001, Gastroenterology.

[37]  D. Valla,et al.  Recent Portal or Mesenteric Venous Thrombosis: Increased Recognition and Frequent Recanalization on Anticoagulant Therapy , 2000, Hepatology.

[38]  Y. Chawla,et al.  Biliary changes in extrahepatic portal venous obstruction: compression by collaterals or ischemic? , 1999, Gastrointestinal endoscopy.

[39]  D. Valla,et al.  Outcome of Budd‐Chiari syndrome: A multivariate analysis of factors related to survival including surgical portosystemic shunting , 1999, Hepatology.

[40]  R. Edelman,et al.  Portal vein thrombosis: a review. , 1992, The American journal of medicine.

[41]  N Ragavendra,et al.  Diagnosis of portal vein thrombosis: value of color Doppler imaging. , 1991, AJR. American journal of roentgenology.